image credit: Freepik

FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer

September 21, 2021


DTC is usually treated with surgery, followed by the removal of the remaining thyroid tissues with radioiodine. However, approximately 5% to 15% of cases are resistant to radioiodine treatment, with these patients carrying a life expectancy of only three to five years from the time metastatic lesions are detected.

Previously, Exelixis announced that a clinical trial evaluating Cabometyx in this tough-to-treat population met one of the two primary endpoints of significant improvement versus placebo in progression-free survival (PFS).

Read More on Pharma Times